Moderna 8-K: Executive Changes & Financials
Ticker: MRNA · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1682852
| Field | Detail |
|---|---|
| Company | Moderna, Inc. (MRNA) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-composition, financials
Related Tickers: MRNA
TL;DR
Moderna 8-K dropped: exec changes, new directors, and financials filed.
AI Summary
Moderna, Inc. filed an 8-K on October 2, 2024, reporting on events as of September 28, 2024. The filing primarily concerns the departure of certain officers, the election of new directors, and updates to compensatory arrangements for key executives. It also includes financial statements and exhibits.
Why It Matters
This filing provides insight into potential leadership shifts and executive compensation strategies at Moderna, which could impact investor confidence and future company direction.
Risk Assessment
Risk Level: medium — Changes in executive officers and directors, along with updates to compensation, can signal internal shifts that may affect company strategy and performance.
Key Players & Entities
- Moderna, Inc. (company) — Registrant
- September 28, 2024 (date) — Date of earliest event reported
- October 2, 2024 (date) — Date of report
- 325 Binney Street, Cambridge, MA 02142 (address) — Principal executive offices
FAQ
What specific officer positions are affected by the departures mentioned in the filing?
The filing indicates 'Departure of Directors or Certain Officers' as an item of report, but does not specify the exact positions in the provided text.
Who are the newly elected directors?
The filing lists 'Election of Directors' as an item of report, but the names of the newly elected directors are not detailed in the provided text.
What are the key changes in compensatory arrangements for officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of report, but the specifics of these arrangements are not elaborated in the provided text.
What is the significance of the 'Regulation FD Disclosure' item?
This indicates that the filing may contain information that is being disclosed to the public in compliance with Regulation Fair Disclosure, ensuring broad dissemination of material non-public information.
When was Moderna, Inc. previously known as Moderna Therapeutics, Inc.?
The filing states that the date of the name change from Moderna Therapeutics, Inc. to Moderna, Inc. was August 22, 2016.
Filing Stats: 842 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-10-02 07:03:59
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market
Filing Documents
- mrna-20240928.htm (8-K) — 32KB
- exhibit991-1022024.htm (EX-99.1) — 9KB
- 0001682852-24-000052.txt ( ) — 165KB
- mrna-20240928.xsd (EX-101.SCH) — 2KB
- mrna-20240928_lab.xml (EX-101.LAB) — 21KB
- mrna-20240928_pre.xml (EX-101.PRE) — 12KB
- mrna-20240928_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 2, 2024, the Company issued a press release announcing the appointment of Mr. Hussain to the Board. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Moderna, Inc. dated October 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 2, 2024 MODERNA, INC. By: /s/ Shannon Thyme Klinger Shannon Thyme Klinger Chief Legal Officer